Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 27Neoplasm Metastasis 15Ovarian Neoplasms 5Brain Neoplasms 4Neoplasms 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Advanced Breast Cancer 2Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic HER2-positive Breast Cancer 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Ketosis 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HR+HER2- Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-negative Metastatic Breast Cancer 1

Interventions

eribulin 3Vinorelbine 2Paclitaxel 2Epirubicin 2Doxorubicin 2Cyclophosphamide 2trastuzumab deruxtecan 1tislelizumab 1taxane 1sacituzumab govitecan 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1camrelizumab 1anlotinib 1Taxes 1Precision Medicine 1Gemcitabine 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1Anthracyclines 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HER2-negative Breast Cancer × eribulin × Breast × Clear all
NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting
252 enrolled
Breast

HER2-negative Breast Cancer

NCT05263882 2022-03-03

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

Fifth Affiliated Hospital, Sun Yat-Sen University

Phase 2 Unknown
58 enrolled
Breast

HER2-negative Breast Cancer

NCT04624711 2021-05-21

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
40 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡